The FDA Voted for 6 Peptides. Its Own Scientists Said No

The FDA Voted for 6 Peptides. Its Own Scientists Said No

August 7, 2026 · 1h 6m · Episode 410

About this episode

Dr. Jordan Feigenbaum discusses the implications of the FDA advisory committee's vote on peptides, despite objections from its own scientists.

An FDA advisory committee just voted to open a legal compounding supply line for six of seven peptides, including BPC-157 and TB-500, over the objection of the FDA's own scientists, who recommended against all seven. Dr. Jordan Feigenbaum walks through what the Pharmacy Compounding Advisory Committee actually voted on, why a vote about ulcerative colitis ends up governing tendon and joint use, what the single human BPC-157 trial does and doesn't show, and why "a pharmacy makes it safe" and "there's no money to study it" don't hold up. Evidence-based, no hype, no nocebo. Timestamps: | 00:00:00 | The FDA voted 8-6. What it actually means | 00:01:25 | What I am, and am not, claiming | 00:03:21 | How they got here: Category 2 and the paperwork | 00:07:17 | Who was in the room: the panel that flipped | 00:10:57 | What they voted on: compounding and the bulks list | 00:15:37 | "No money in it, you can't patent it" | 00:18:24 | The trials already run: Plevna and MK-677 | 00:22:55 | "I took it and it worked": placebo and fake surgery | 00:27:02 | The one human trial: Ruenzi 2005 | 00:32:28 | Is it natural? Is it even a drug? | 00:36:58 | Harm reduction, or follow the money? | 00:42:45 |…

People in this episode

Host: Dr. Jordan Feigenbaum

Topics covered

Keywords

Mentioned in this episode

Organizations: FDA, Pharmacy Compounding Advisory Committee

Products: BPC-157, TB-500

Books & works: Ruenzi 2005, Plevna, MK-677

More episodes of Barbell Medicine Podcast

Explore listener stats, chart rankings, contacts and more on the Barbell Medicine Podcast podcast page.